Clinical trial · Interventional
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Etude de Recherche de Dose de l'Association Irinotecan (Campto(R)) - Cisplatine (Cisplatyl(R)) Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de l'utérus.
NCT00251888CI-TRIAL-00025619completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervix Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| campto (irinotecan) | Drug | — | UNRESOLVED |
| cisplatin (cisplatyl) | Drug | Cisplatin | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To determine the maximum tolerated dose of irinotecan associated with cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer
Secondary outcomes (5)
- measure
- To evaluate :
- measure
- the global response rate judged on standard clinical criteria, echography, tomodensiometry, and MRI. The histologic response rate will be appreciated in patients who had a second surgery after pelvic radiochemotherapy
- measure
- local and general relapse frequency
- measure
- progression free survival
- measure
- global survival
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven primitive epidermoid or andenocarcinoma Cervix * FIGO stage IIB (obviously parameter attack), III or IVA * No previous chemotherapy nor radiotherapy * Patient for whom a radiochemotherapy is envisaged as first intention treatmentof her cervix carcinoma * PS ECOG \< 2 * Life expectancy \> 12 weeks * Written consent given Exclusion Criteria: * Other malignant cervix tumor histology * Visceral remotly metastasis * Other malignant tumor since 5 years, except spino or baso-cellular treaten and cured cancer * Anormal labs values * Peripheric neuropathy CTC \> 2 * Auditory loss \> 2 * Cardiopathy * Inflammatory digestive pathology * Evolutive infection * Other experimental concommitant treatment * Lacting or pregnant women
References
Publications (0)
Data not yet available
No reference posted for this study.